Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche shareholders approve deal to buy Novartis's $20.7 billion stake

11/26/2021 | 05:19am EST

ZURICH, Nov 26 (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.

Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.

Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.

They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.

Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.

"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche," said Roche Chairman Christoph Franz. "As a result, we will be even better positioned to make a contribution to the health of people around the world."

Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.

The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.

Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.

Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis. (Reporting by John Revill, editing by Silke Koltrowitz)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG -1.87% 79.87 Delayed Quote.-0.51%
ROCHE HOLDING AG -1.22% 360.65 Delayed Quote.-4.87%
UBS GROUP AG -1.07% 17.49 Delayed Quote.6.52%
All news about ROCHE HOLDING AG
01/20Credit Suisse Vice Chair Yet To Decide About Reelection At April Meeting
01/20Credit Suisse Vice Chairman Unsure Whether He Will Stay on Board, Tages-Anzeiger Report..
01/20SEVERIN SCHWAN : Credit Suisse Vice-Chair Schwan undecided whether to stay on board -paper
01/17ROCHE : virtual event on key ophthalmology data presented at the Angiogenesis 2022 Meeting
01/17ROCHE HOLDINGS AG : Buy rating from Deutsche Bank
01/17GMP production of CG01 made available for preclinical studies planned to enable First i..
01/13ROCHE HOLDINGS AG : JP Morgan gives a Neutral rating
01/12Biogen shares slide as Medicare proposal restricts coverage of Alzheimer's treatments
01/12Oncolytics Biotech Releases a Letter to Shareholders - 2021 Review and 2022 Outlook
01/12Roche launches the cobas« pulse system, an industry first professional blood glucose ma..
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Sales 2021 62 399 M 68 395 M 68 395 M
Net income 2021 15 017 M 16 460 M 16 460 M
Net Debt 2021 7 316 M 8 019 M 8 019 M
P/E ratio 2021 20,0x
Yield 2021 2,75%
Capitalization 292 B 320 B 320 B
EV / Sales 2021 4,79x
EV / Sales 2022 4,72x
Nbr of Employees 101 465
Free-Float -
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 360,65 CHF
Average target price 404,97 CHF
Spread / Average Target 12,3%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Pascale Schmidt Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-4.87%319 830
JOHNSON & JOHNSON-3.40%435 037
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833